

The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.

The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM D

Notice of Exempt Offering of Securities

| OMB APPROVAL | |
|--|-----------|
| OMB Number: | 3235-0076 |
| Estimated average burden hours per response: | 4.00 |

1. Issuer's Identity

| | | |
|---|--|--|
| CIK (Filer ID Number) 0001649989 | Previous Names None Oncobiologics, Inc. | Entity Type <input checked="" type="checkbox"/> Corporation <input type="checkbox"/> Limited Partnership <input type="checkbox"/> Limited Liability Company <input type="checkbox"/> General Partnership <input type="checkbox"/> Business Trust <input type="checkbox"/> Other (Specify) |
| Name of Issuer Outlook Therapeutics, Inc. | | |
| Jurisdiction of Incorporation/Organization DELAWARE | | |
| Year of Incorporation/Organization <input checked="" type="checkbox"/> Over Five Years Ago <input type="checkbox"/> Within Last Five Years (Specify Year) <input type="checkbox"/> Yet to Be Formed | | |

2. Principal Place of Business and Contact Information

| | | | |
|---|---|--------------------------------|---|
| Name of Issuer Outlook Therapeutics, Inc. | | | |
| Street Address 1 7 CLARKE DRIVE | | Street Address 2 | |
| City CRANBURY | State/Province/Country NEW JERSEY | ZIP/PostalCode 08512 | Phone Number of Issuer 6096193990 |

3. Related Persons

| | | |
|--|---|--------------------------------|
| Last Name Thurman | First Name Randy | Middle Name |
| Street Address 1 c/o Outlook Therapeutics, Inc. | Street Address 2 7 Clarke Drive | |
| City CRANBURY | State/Province/Country NEW JERSEY | ZIP/PostalCode 08512 |
| Relationship: Executive Officer <input checked="" type="checkbox"/> Director <input type="checkbox"/> Promoter <input type="checkbox"/> | | |

Clarification of Response (if Necessary):

| | | |
|--|---|--------------------------------|
| Last Name Haddadin | First Name Yezan | Middle Name |
| Street Address 1 c/o Outlook Therapeutics, Inc. | Street Address 2 7 Clarke Drive | |
| City CRANBURY | State/Province/Country NEW JERSEY | ZIP/PostalCode 08512 |
| Relationship: Executive Officer <input checked="" type="checkbox"/> Director <input type="checkbox"/> Promoter <input type="checkbox"/> | | |

Clarification of Response (if Necessary):

| Last Name | First Name | Middle Name |
|--|-------------------------------|-----------------------|
| Hilzinger | Kurt | J. |
| Street Address 1 | Street Address 2 | |
| c/o Outlook Therapeutics, Inc. | 7 Clarke Drive | |
| City | State/Province/Country | ZIP/PostalCode |
| CRANBURY | NEW JERSEY | 08512 |
| Relationship: Executive Officer X Director Promoter | | |

Clarification of Response (if Necessary):

| Last Name | First Name | Middle Name |
|--|-------------------------------|-----------------------|
| Kenyon | Lawrence | A. |
| Street Address 1 | Street Address 2 | |
| c/o Outlook Therapeutics, Inc. | 7 Clarke Drive | |
| City | State/Province/Country | ZIP/PostalCode |
| CRANBURY | NEW JERSEY | 08512 |
| Relationship: X Executive Officer X Director Promoter | | |

Clarification of Response (if Necessary):

| Last Name | First Name | Middle Name |
|--|-------------------------------|-----------------------|
| Sukhtian | Faisal | G. |
| Street Address 1 | Street Address 2 | |
| c/o Outlook Therapeutics, Inc. | 7 Clarke Drive | |
| City | State/Province/Country | ZIP/PostalCode |
| CRANBURY | NEW JERSEY | 08512 |
| Relationship: Executive Officer X Director Promoter | | |

Clarification of Response (if Necessary):

| Last Name | First Name | Middle Name |
|--|-------------------------------|-----------------------|
| Dagnon | Terry | |
| Street Address 1 | Street Address 2 | |
| c/o Outlook Therapeutics, Inc. | 7 Clarke Drive | |
| City | State/Province/Country | ZIP/PostalCode |
| Cranbury | NEW JERSEY | 08512 |
| Relationship: X Executive Officer Director Promoter | | |

Clarification of Response (if Necessary):

| Last Name | First Name | Middle Name |
|--|-------------------------------|-----------------------|
| Evanson | Jeff | |
| Street Address 1 | Street Address 2 | |
| c/o Outlook Therapeutics, Inc. | 7 Clarke Drive | |
| City | State/Province/Country | ZIP/PostalCode |
| Cranbury | NEW JERSEY | 08512 |
| Relationship: X Executive Officer Director Promoter | | |

Clarification of Response (if Necessary):

4. Industry Group

| | | |
|------------------------------|------------------|-------------|
| Agriculture | Health Care | Retailing |
| Banking & Financial Services | Biotechnology | Restaurants |
| Commercial Banking | Health Insurance | Technology |
| Insurance | | |

Investing
Investment Banking
Pooled Investment Fund
Is the issuer registered as an investment company under the Investment Company Act of 1940?
Yes No
Other Banking & Financial Services
Business Services
Energy
Coal Mining
Electric Utilities
Energy Conservation
Environmental Services
Oil & Gas
Other Energy

Hospitals & Physicians
Pharmaceuticals
Other Health Care
Manufacturing
Real Estate
Commercial
Construction
REITS & Finance
Residential
Other Real Estate

Computers
Telecommunications
Other Technology
Travel
Airlines & Airports
Lodging & Conventions
Tourism & Travel Services
Other Travel
X Other

5. Issuer Size

| Revenue Range | OR | Aggregate Net Asset Value Range |
|------------------------------|-----------|--|
| No Revenues | | No Aggregate Net Asset Value |
| \$1 - \$1,000,000 | | \$1 - \$5,000,000 |
| \$1,000,001 - \$5,000,000 | | \$5,000,001 - \$25,000,000 |
| \$5,000,001 - \$25,000,000 | | \$25,000,001 - \$50,000,000 |
| \$25,000,001 - \$100,000,000 | | \$50,000,001 - \$100,000,000 |
| Over \$100,000,000 | | Over \$100,000,000 |
| X Decline to Disclose | | Decline to Disclose |
| Not Applicable | | Not Applicable |

6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)

| | Investment Company Act Section 3(c) | |
|---|-------------------------------------|------------------|
| Rule 504(b)(1) (not (i), (ii) or (iii)) | Section 3(c)(1) | Section 3(c)(9) |
| Rule 504 (b)(1)(i) | Section 3(c)(2) | Section 3(c)(10) |
| Rule 504 (b)(1)(ii) | Section 3(c)(3) | Section 3(c)(11) |
| Rule 504 (b)(1)(iii) | Section 3(c)(4) | Section 3(c)(12) |
| X Rule 506(b) | Section 3(c)(5) | Section 3(c)(13) |
| Rule 506(c) | Section 3(c)(6) | Section 3(c)(14) |
| Securities Act Section 4(a)(5) | Section 3(c)(7) | |

7. Type of Filing

X New Notice Date of First Sale 2020-02-24 First Sale Yet to Occur
Amendment

8. Duration of Offering

Does the Issuer intend this offering to last more than one year? Yes X No

9. Type(s) of Securities Offered (select all that apply)

| | |
|---|----------------------------------|
| <input checked="" type="checkbox"/> Equity | Pooled Investment Fund Interests |
| <input type="checkbox"/> Debt | Tenant-in-Common Securities |
| <input checked="" type="checkbox"/> Option, Warrant or Other Right to Acquire Another Security | Mineral Property Securities |
| <input checked="" type="checkbox"/> Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security | Other (describe) |

10. Business Combination Transaction

Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer? Yes No

Clarification of Response (if Necessary):

11. Minimum Investment

Minimum investment accepted from any outside investor \$0 USD

12. Sales Compensation

| | | |
|--|--|--|
| Recipient | Recipient CRD Number | None |
| H.C. Wainwright & Co., LLC | 375 | |
| (Associated) Broker or Dealer <input checked="" type="checkbox"/> None | (Associated) Broker or Dealer CRD Number | <input checked="" type="checkbox"/> None |
| None | None | |

Street Address 1

Street Address 2

430 Park Avenue

| | |
|----------|------------------------|
| City | State/Province/Country |
| New York | NEW YORK |

ZIP/Postal Code
10022

State(s) of Solicitation (select all that apply)
 Check "All States" or check individual States All States Foreign/non-US

| |
|------------|
| ILLINOIS |
| NEW JERSEY |
| NEW YORK |

13. Offering and Sales Amounts

| | | | |
|----------------------------|-----------------|----|------------|
| Total Offering Amount | \$7,971,155 USD | or | Indefinite |
| Total Amount Sold | \$7,971,155 USD | | |
| Total Remaining to be Sold | \$0 USD | or | Indefinite |

Clarification of Response (if Necessary):

Includes amounts receivable upon the exercise of warrants; such warrants have not yet been exercised

14. Investors

Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, and enter the number of such non-accredited investors who already have invested in the offering. _____
 Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering: 7

15. Sales Commissions & Finder's Fees Expenses

Provide separately the amounts of sales commissions and finders fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.

| | | |
|-------------------|---------------|-----------------------------------|
| Sales Commissions | \$540,400 USD | <input type="checkbox"/> Estimate |
| Finders' Fees | \$0 USD | <input type="checkbox"/> Estimate |

Clarification of Response (if Necessary):

In addition, the placement agent was reimbursed \$135,000 for expenses relating to the offering and received \$77,200 for management fees.

16. Use of Proceeds

Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

\$0 USD Estimate

Clarification of Response (if Necessary):

Signature and Submission

Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

Terms of Submission

In submitting this notice, each issuer named above is:

- Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.*
- Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against the issuer in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
- Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Rule 504 or Rule 506 for one of the reasons stated in Rule 504(b)(3) or Rule 506(d).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

| Issuer | Signature | Name of Signer | Title | Date |
|----------------------------|---------------------|-----------------|-------------------------|------------|
| Outlook Therapeutics, Inc. | /s/ Lawrence Kenyon | Lawrence Kenyon | Chief Executive Officer | 2020-03-10 |

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

* This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.